In addition, dCAR-modified CD4+ T cells also have cytotoxicity against cognate tumor cells (approximately 30%); therefore, CD4+ T cells possess lower target cell killing capacity compared with CD8+ T cells (Additional file 1: Figure S4). The gene discussed is CD8A; the disease is neoplasm.